258 related articles for article (PubMed ID: 16501005)
1. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro.
Dai Y; Hebert MF; Isoherranen N; Davis CL; Marsh C; Shen DD; Thummel KE
Drug Metab Dispos; 2006 May; 34(5):836-47. PubMed ID: 16501005
[TBL] [Abstract][Full Text] [Related]
2. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
[TBL] [Abstract][Full Text] [Related]
3. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
Kamdem LK; Streit F; Zanger UM; Brockmöller J; Oellerich M; Armstrong VW; Wojnowski L
Clin Chem; 2005 Aug; 51(8):1374-81. PubMed ID: 15951320
[TBL] [Abstract][Full Text] [Related]
4. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.
Zhao Y; Song M; Guan D; Bi S; Meng J; Li Q; Wang W
Transplant Proc; 2005; 37(1):178-81. PubMed ID: 15808586
[TBL] [Abstract][Full Text] [Related]
6. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
8. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
9. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
11. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
[TBL] [Abstract][Full Text] [Related]
12. Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients.
Ferraresso M; Tirelli A; Ghio L; Grillo P; Martina V; Torresani E; Edefonti A
Pediatr Transplant; 2007 May; 11(3):296-300. PubMed ID: 17430486
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
Tada H; Tsuchiya N; Satoh S; Kagaya H; Li Z; Sato K; Miura M; Suzuki T; Kato T; Habuchi T
Transplant Proc; 2005 May; 37(4):1730-2. PubMed ID: 15919447
[TBL] [Abstract][Full Text] [Related]
14. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
Isoherranen N; Ludington SR; Givens RC; Lamba JK; Pusek SN; Dees EC; Blough DK; Iwanaga K; Hawke RL; Schuetz EG; Watkins PB; Thummel KE; Paine MF
Drug Metab Dispos; 2008 Jan; 36(1):146-54. PubMed ID: 17954524
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole.
Chandel N; Aggarwal PK; Minz M; Sakhuja V; Kohli KK; Jha V
Pharmacogenet Genomics; 2009 Jun; 19(6):458-63. PubMed ID: 19384264
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.
Chen JS; Li LS; Cheng DR; Ji SM; Sun QQ; Cheng Z; Wen JQ; Sha GZ; Liu ZH
Transplant Proc; 2009 Jun; 41(5):1557-61. PubMed ID: 19545678
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A5 genetic polymorphism on cross-reactivity in tacrolimus chemiluminescent immunoassay in kidney transplant recipients.
Hirano K; Naito T; Mino Y; Takayama T; Ozono S; Kawakami J
Clin Chim Acta; 2012 Dec; 414():120-4. PubMed ID: 22889968
[TBL] [Abstract][Full Text] [Related]
18. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
19. Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes.
Dennison JB; Mohutsky MA; Barbuch RJ; Wrighton SA; Hall SD
J Pharmacol Exp Ther; 2008 Oct; 327(1):248-57. PubMed ID: 18650247
[TBL] [Abstract][Full Text] [Related]
20. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
